Parnell Pharmaceuticals Holdings Ltd
Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproduc… Read more
Parnell Pharmaceuticals Holdings Ltd (PARNF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2019: 0.000x
Based on the latest financial reports, Parnell Pharmaceuticals Holdings Ltd (PARNF) has a cash flow conversion efficiency ratio of 0.000x as of June 2019.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($0.00) by net assets ($-308.48K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Parnell Pharmaceuticals Holdings Ltd - Cash Flow Conversion Efficiency Trend (2011–2021)
This chart illustrates how Parnell Pharmaceuticals Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Parnell Pharmaceuticals Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Parnell Pharmaceuticals Holdings Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GREAT WORLD CO HLDG
BE:TTQ
|
N/A |
|
Mobilityone Ltd
LSE:MBO
|
0.906x |
|
Quice Food Industries Ltd
KAR:QUICE
|
N/A |
|
Sakana SA
WAR:SKN
|
0.160x |
|
VITAFOAM NIGERIA PLC
XNSA:VITAFOAM
|
N/A |
|
BJNS -H- (BJ3.SG)
STU:BJ3
|
-0.029x |
|
United Brands Ltd
KAR:UBDL
|
N/A |
|
MING FAI INTERNATIO
BE:36Y
|
N/A |
Annual Cash Flow Conversion Efficiency for Parnell Pharmaceuticals Holdings Ltd (2011–2021)
The table below shows the annual cash flow conversion efficiency of Parnell Pharmaceuticals Holdings Ltd from 2011 to 2021.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2021-12-31 | $-34.79 Million | $5.45K | 0.000x | -204.91% |
| 2020-12-31 | $-31.85 Million | $-4.76K | 0.000x | +272.76% |
| 2019-12-31 | $-26.23 Million | $2.27K | 0.000x | -100.10% |
| 2018-12-31 | $-18.53 Million | $-1.62 Million | 0.087x | -46.55% |
| 2017-12-31 | $-11.32 Million | $-1.85 Million | 0.163x | +110.88% |
| 2016-12-31 | $8.06 Million | $-12.12 Million | -1.502x | -85.37% |
| 2015-12-31 | $20.25 Million | $-16.42 Million | -0.811x | -77.48% |
| 2014-12-31 | $25.09 Million | $-11.46 Million | -0.457x | +63.42% |
| 2013-12-31 | $2.39 Million | $-2.98 Million | -1.248x | -330.54% |
| 2011-12-31 | $6.58 Million | $3.56 Million | 0.542x | -- |